Table 1 Patient sample characteristics
| Â | Control (n = 1025) | Intervention (n = 1103) | Total (n = 2128) |
|---|---|---|---|
Gender, n (%) | |||
 Female | 739 (73.3) | 543 (50.3) | 1282 (61.4) |
 Male | 265 (26.3) | 536 (49.7) | 801 (38.4) |
 Other or not specified | 4 (0.4) | 0 (0.0) | 4 (0.2) |
Age, mean (SD) | |||
 Years | 56.3 (16.2) | 57.8 (15.7) | 57.0 (15.9) |
Formal education, n (%) | |||
 Low a | 185 (18.6) | 216 (20.2) | 401 (19.4) |
 Intermediate b | 307 (30.8) | 326 (39.5) | 633 (30.7) |
 High c | 236 (23.7) | 234 (21.8) | 470 (22.7) |
 Very high d | 260 (26.1) | 284 (26.6) | 544 (26.3) |
 Other | 8 (0.8) | 9 (0.8) | 17 (0.8) |
Occupational status e, n (%) | |||
 (Self-)employed | 442 (44.1) | 476 (44.5) | 918 (44.3) |
 Retired | 433 (43.2) | 470 (43.9) | 903 (43.6) |
 Homemaker | 61 (6.1) | 44 (4.1) | 105 (5.1) |
 Other f (< 5% each) | 110 (11.0) | 117 (10.9) | 227 (11.0) |
Setting, n (%) | |||
 Inpatient | 89 (8.7) | 93 (8.4) | 182 (8.6) |
 Outpatient | 934 (91.3) | 1010 (91.6) | 1944 (91.4) |
Global health, mean (SD) | |||
 1 to 5, higher better | 2.83 (0.85) | 2.79 (0.85) | 2.81 (0.85) |
Distress, mean (SD) | |||
 0 to 10, higher more | 5.67 (2.48) | 5.43 (2.45) | 5.55 (2.47) |
Diagnosis, n (%) | |||
 Confirmed malignant neoplasm | 759 (82.0) | 826 (83.1) | 1585 (82.6) |
 Suspected malignant neoplasm | 11 (1.2) | 9 (0.9) | 20 (1.0) |
 In situ neoplasm or neoplasm of uncertain behavior | 19 (2.1) | 35 (3.5) | 54 (2.8) |
 Benign neoplasm | 30 (3.2) | 11 (1.1) | 41 (2.1) |
 Other diagnosis | 107 (11.6) | 113 (11.4) | 220 (11.5) |
Time since initial diagnosis, n (%) | |||
 1 year or less | 393 (47.9) | 390 (42.0) | 783 (44.8) |
 1 to 5 years | 279 (34.0) | 370 (39.9) | 649 (37.1) |
 more than 5 years | 148 (18.0) | 168 (18.1) | 316 (18.1) |
Reason for visit e, g, n (%) | |||
 Diagnostic investigation | 235 (23.5) | 214 (20.0) | 449 (21.7) |
 Initial communication of the diagnosis | 165 (16.6) | 158 (14.9) | 323 (15.7) |
 Treatment planning | 278 (27.9) | 249 (23.4) | 527 (25.6) |
 Treatment | 167 (16.8) | 239 (22.5) | 406 (19.7) |
 Treatment monitoring | 254 (25.5) | 338 (31.8) | 592 (28.8) |
 Aftercare | 205 (20.6) | 216 (20.3) | 421 (20.4) |
Decision topic e, g, n (%) | |||
 Diagnostic procedures | 314 (33.1) | 296 (29.2) | 610 (31.1) |
 Surgery | 304 (32.0) | 257 (25.3) | 561 (28.6) |
 Chemotherapy | 207 (21.8) | 379 (37.3) | 586 (29.8) |
 Radiation therapy | 69 (7.3) | 101 (10.0) | 170 (8.7) |
 Other treatment | 100 (10.5) | 99 (9.8) | 199 (10.1) |
Surveyed in pandemic, n (%) | |||
 No | 993 (100.0) | 711 (66.7) | 1704 (82.8) |
 Yes | 0 (0.0) | 355 (33.3) | 355 (17.2) |